The PD-1 project of Dongfang Baitai has been awarded the Beijing-Tianjin-Hebei Collaborative Innovation Excellence Award.
[Summary Description]
In May 2017, the eleventh Beijing Invention and Innovation Competition’s selection and award ceremony for the Beijing–Tianjin–Hebei Collaborative Innovation Award was held at the Peking University Building. During the event, on-site evaluations were conducted for the special award in the field of Beijing–Tianjin–Hebei coordinated development, and all winning entries were announced and presented with their respective awards. The entry submitted by Beijing Dongfang Baitai Biotechnology Co., Ltd.—a monoclonal antibody against PD‑1 and its preparation method—was awarded the Excellent Prize for Beijing–Tianjin–Hebei Collaborative Innovation.
In May 2017, the eleventh Beijing Invention and Innovation Competition’s selection and award ceremony for the Beijing–Tianjin–Hebei Collaborative Innovation Award was held at the Peking University Building. During the event, on-site evaluations were conducted for the special award in the field of Beijing–Tianjin–Hebei coordinated development, and all winning entries were announced and presented with their respective awards. The entry submitted by Beijing Dongfang Baitai Biotechnology Co., Ltd.—a monoclonal antibody against PD‑1 and its preparation method—was awarded the Excellent Prize for Beijing–Tianjin–Hebei Collaborative Innovation.

This year’s Beijing Invention and Innovation Competition is hosted by the Zhongguancun Federation of Social Organizations and organized by the Beijing Invention Association. Since the launch of the major strategic initiative for coordinated development of the Beijing–Tianjin–Hebei region in 2014, a powerful symphony of regional collaboration has been unfolding across China over the past three years. Fundamentally, this coordinated development hinges on innovation-driven growth and scientific and technological advancement—key measures that are unlocking new momentum for economic development, propelling industrial upgrading, and creating fresh opportunities for high‑end talent and cutting‑edge technologies. Notably, innovation in the biopharmaceutical sector has been designated as a priority area within this broader framework of coordinated development.
Monoclonal antibody therapeutics represent the most technologically demanding and highest‑level segment of the biopharmaceutical industry, while also commanding the largest market share. They serve as a driving force behind the sector’s growth, and their level of development has become a key indicator of a nation’s overall biopharmaceutical advancement.
Through phage‑display technology, Dongfang Baitai has identified JY034, a fully human monoclonal antibody with high affinity for the programmed cell death protein 1 (PD‑1) receptor. By independently developing this PD‑1‑targeting antibody, Dongfang Baitai has established a cutting‑edge monoclonal antibody R&D platform that is protected by China’s own intellectual property rights, overcoming numerous technical barriers that have long constrained the rapid growth of China’s antibody‑drug industry. The company has also cultivated and assembled a world‑class team specializing in antibody drug research and industrial translation, thereby catalyzing a leap‑forward development of China’s antibody sector. JY034 has been granted a Chinese invention patent and, through a PCT application, has entered 18 countries and regions, including Europe, Eurasia, the United States, Japan, South Korea, and Canada, and is currently in the preclinical development stage.
Multiple clinical studies have demonstrated that treatment with PD‑1 inhibitor antibodies can significantly improve survival outcomes in patients with more than ten types of cancer, including lung cancer, renal cell carcinoma, melanoma, lymphoma, head and neck cancer, bladder cancer, triple‑negative breast cancer, hepatocellular carcinoma, gastric cancer, esophageal cancer, colorectal cancer, and glioma. Owing to the remarkable efficacy these agents have shown in cancer immunotherapy, they have rightfully earned their status as the most prominent star drugs in the field of oncology.
Several multinational pharmaceutical companies are racing to develop monoclonal antibody drugs targeting PD‑1. Among them, Merck’s pembrolizumab and Bristol‑Myers Squibb’s nivolumab were approved by the U.S. FDA for marketing in September and December 2014, respectively, with melanoma and non‑small cell lung cancer as their initial indications. Subsequently, their approved indications have been expanded to include advanced renal cell carcinoma, colorectal cancer, gastric cancer, and more than 30 other cancer types, while demonstrating favorable safety profiles and durable tumor responses in clinical practice, suggesting broad prospects for clinical application.
At present, no comparable drug is yet available on the Chinese market. JY034 has demonstrated promising in vitro efficacy; its development not only addresses the clinical need for such agents in China but also holds the potential to improve patient survival more effectively than existing products, thereby exhibiting significant value for both drug development and clinical application.
The PD‑1 monoclonal antibody developed independently by Dongfang Baitai will bolster China’s antibody‑drug industry’s innovation capacity. Successful translation of research findings will enable a large number of Chinese cancer patients to access and afford antibody therapies, while also positioning domestically produced monoclonal antibodies to compete on the global stage and establish a distinctive national brand in the antibody field.
The receipt of numerous honors underscores Dongfang Baitai’s innovative strength in the biopharmaceutical monoclonal antibody field: its cutting-edge R&D platform is aligning with international standards, and its innovation-driven R&D system continues to evolve, instilling lasting confidence in the company’s team. We will remain committed to leveraging scientific and technological innovation to enhance our capabilities in the independent R&D and industrialization of antibody therapeutics, accelerate the launch of a portfolio of groundbreaking monoclonal antibody drugs, and swiftly elevate the overall standing and international competitiveness of China’s antibody industry.
A warm welcome to Vice Mayor Lin Keqing for his visit and guidance at Dongfang Baitai.
On October 24, 2016, Beijing Vice Mayor Lin Keqing and his delegation visited Beijing Dongfang Baitai Biotechnology Co., Ltd. and Baitai Bio-pharmaceutical Co., Ltd., conducted an in-depth review of the companies’ R&D progress, inspected the production workshops on-site, and engaged in cordial discussions.
Leave a Message Online Online Message